Stockscreener 앱 받기
55.26
2.40%
-1.36
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth - Chartmill
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai - Endpoints News
Another ADC foray for Bristol Myers Squibb - The Pharma Letter
Campbell & CO Investment Adviser LLC Has $5.81 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Camzyos’ Phase 3 Adolescent oHCM Win - simplywall.st
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Immunai and Bristol Myers Squibb turn to AI to decode immune responses in clinical trials - CTech
Stephens Inc. AR Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Trading 1.9% Higher After Analyst Upgrade - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares - MarketBeat
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients - Finviz
Bristol Says New Version of Opdivo on Track to Meet Target - Bloomberg
Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY) - The Globe and Mail
Manning & Napier Advisors LLC Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Leerink Partners Raises Price Target for Bristol-Myers Squibb (B - GuruFocus
Leerink Partners Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price - MarketBeat
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Pharmaceutical Technology
Bristol-Myers Squibb stock price target raised to $60 from $54 at Leerink - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
Worldwide locations - Bristol Myers Squibb
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
Bristol Myers Squibb CEO Outlines 2030 Growth Strategy Focused on Oncology, Immunology, and Cardiovascular Expansion at JP Morgan Healthcare Conference - geneonline.com
Bristol-Myers Squibb Stock Under Pressure: Is This Deep-Value Pharma Name Finally Near a Turning Poi - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Releases New Investor Presentation - GuruFocus
Bristol-Myers Squibb Advances Liver Cancer Combo as Key Trial Reaches Completion - TipRanks
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth - Insider Monkey
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release - Barchart.com
Bristol Myers Squibb’s Camzyos shows positive results in adolescent oHCM trial - Investing.com
BMY Reports Positive Results from Phase 3 SCOUT-HCM Trial - GuruFocus
First Horizon Corp Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: A Pivotal Year Ahead as Sentiment Shifts - AD HOC NEWS
Nepsis Inc. Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Lecap Asset Management Ltd. Sells 19,756 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story - Yahoo Finance
Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - Yahoo Finance
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Scotiabank raises Bristol-Myers Squibb stock price target to $60 on growth - Investing.com
Next Level Private LLC Has $2.54 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating - marketscreener.com
Privacy notice center - Bristol Myers Squibb
What RSI levels show for Bristol Myers Squibb Company (BRM) stockStock Surge & AI Enhanced Execution Alerts - ulpravda.ru
Is Bristol Myers Squibb Company Celegne Contingent stock attractive post correctionMarket Performance Report & Consistent Growth Equity Picks - ulpravda.ru
Will Bristol Myers Squibb Company stock outperform foreign stocksJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - ulpravda.ru
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
SG Americas Securities LLC Has $75.53 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
BMS-partnered ADC shows first Phase III success in hard-to-treat cancer - The Pharma Letter
Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb (BMY) Quietly Recasting Its Post-Patent Story With Opdivo And KarXT Moves? - simplywall.st
Bristol-Myers' buy of Celgene gets endorsement from top Wall Street advisory firms - The Pharma Letter
Bristol-Myers Squibb (BMY) Upgraded to Buy with Raised Price Tar - GuruFocus
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
3 Drug Stocks to Buy at a Discount - Finviz
Bristol-Myers Squibb stock upgraded to Buy at UBS on promising 2026 catalysts - Investing.com India
BMY Stock Quote Price and Forecast - CNN
Bristol Myers Squibb : Preliminary Q4 2025 Acquired IPRD & Licensing Income - marketscreener.com
1.85%
3.01%
자본화:
|
볼륨(24시간):